grepcent public filings, reorganized for comparison
This page is a descriptive assembly from a frozen evidence pack of public SEC filing excerpts and verified SEC companyfacts metrics. It is not a rating, recommendation, endorsement, forecast, valuation, or investment advice. Filer viewpoints are attributed to the filer and figures are as of their cited filing dates.
Informational only - not investment advice. See Disclaimer.
Back to MRK company profile. Existing company-page SVG figures remain the source for financial time-series context.
On products and services:
Animal Health The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as an extensive suite of digitally connected identification, traceability and monitoring products.
On reportable segments:
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The values below are templated from verified SEC companyfacts-derived facts. The embedded SVG figures show selected annual series from the same facts.
Reported revenue: 65,011,000,000
Net margin: 28.08%
Free cash flow: 12,360,000,000
Revenue scale is shown from verified SEC companyfacts. Revenue: 65,011,000,000
Net margin is shown from verified SEC companyfacts. Net margin: 28.08%
Free cash flow is computed from verified operating cash flow and capital expenditure facts. Free cash flow: 12,360,000,000
Capital expenditures are shown as reported payment magnitude from verified SEC companyfacts. Capital expenditures: 4,112,000,000
Dividends paid are shown as reported cash outflow magnitude from verified SEC companyfacts. Dividends paid: 8,176,000,000
Share buybacks are shown as reported cash outflow magnitude from verified SEC companyfacts. Share buybacks: 5,084,000,000
| Metric | Value | Fiscal year | Period end | Source |
|---|---|---|---|---|
| Capital expenditures | 4,112,000,000 | 2025 | 2025-12-31 | USD |
| Dividends paid | 8,176,000,000 | 2025 | 2025-12-31 | USD |
| Free cash flow | 12,360,000,000 | 2025 | 2025-12-31 | USD |
| Net income | 18,254,000,000 | 2025 | 2025-12-31 | USD |
| Net margin | 28.08% | 2025 | 2025-12-31 | Percent |
| Operating cash flow | 16,472,000,000 | 2025 | 2025-12-31 | USD |
| Revenue | 65,011,000,000 | 2025 | 2025-12-31 | USD |
| Return on assets | 13.34% | 2025 | 2025-12-31 | Percent |
On competition:
As previously disclosed, while two patents in the Keytruda composition of matter patent family expire in May and November of 2029, respectively, the Company expects these patents to be the subject of litigation and, thus, biosimilar competition could begin in December 2028 when the primary compound patent expires.
On intense product competition:
Also, the Company’s products face intense competition from competitors’ products.
On supply-chain exposure:
These risks could disrupt the Company’s operations and its supply chain, which may result in increased costs.
On healthcare revenue movement:
The international sales decline was primarily due to lower sales of Gardasil/Gardasil 9, Simponi, Lagevrio, Januvia, Bridion, Remicade, and Janumet, partially offset by higher sales of Keytruda, Prevymis, Winrevair, increased alliance revenue from Koselugo and Lynparza, as well as higher sales of animal health products.